<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311505</url>
  </required_header>
  <id_info>
    <org_study_id>B3801001</org_study_id>
    <nct_id>NCT01311505</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)</brief_title>
  <official_title>An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin© 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane®, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is done to demonstrate bioequivalence of rifampicin component in Myrin© 2
      Fixed-Dose Combination Tablet (each contains 75 mg isoniazid and 150 mg rifampicin, Pfizer
      Inc) with equivalent dose of the reference Rimactane® capsule (each contains 300 mg
      rifampicin, Novartis Sandoz) in healthy Filipino male subjects. This study also aims to
      determine the safety and tolerability of Myrin© 2 tablets and Rimactane® capsules in these
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hours (hrs) post-dose</time_frame>
    <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose</time_frame>
    <description>AUC (0-∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-life (t1/2)</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)</measure>
    <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose</time_frame>
    <description>AUC%extrapolated is the extrapolated area under the plasma concentration time profile following the last measured concentration. It is calculated as (AUC [0-∞] minus AUC[0-10])*100/ AUC (0-∞), where AUC (0-∞) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-10) = area under the plasma concentration time-curve from zero (pre-dose) to the last quantifiable concentration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myrin© 2 (Rifampicin + Isoniazid)</intervention_name>
    <description>Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Myrin© 2 (Pfizer Inc.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimactane® (Rifampicin)</intervention_name>
    <description>One (1) capsule of Rifampicin 300 mg</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Rimactane® (Novartis Sandoz)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years, inclusive.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  An informed consent document signed and dated by the subject.

          -  Subjects willing and able to comply with scheduled visits, treatment plan, laboratory
             tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy).

          -  A positive urine drug screen.

          -  History of regular alcohol consumption exceeding 21 drinks/week (1 drink = 5 ounces
             (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of hard liquor)
             within 6 months of screening.

          -  Treatment with an investigational drug within 3 months (or as determined by the local
             requirement, whichever is longer) or 5 half-lives preceding the first dose of study
             medication.

          -  12-lead ECG demonstrating QTc &gt;450 msec at screening. If QTc exceeds 450 msec, the ECG
             should be repeated two more times and the average of the three QTc values should be
             used to determine the subject's eligibility.

          -  History of previous treatment for TB or is suspected of suffering from TB.

          -  Use of prescription or nonprescription drugs and dietary supplements within 7 days or
             5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal
             medication, herbal supplements and hormone replacement therapy must be discontinued 28
             days prior to the first dose of study medication. As an exception, acetaminophen /
             paracetamol may be used at doses of less than 1 g/day. Limited use of non-prescription
             medications that are not believed to affect subject safety or the overall results of
             the study may be permitted on a case-by-case basis following approval by the sponsor.

          -  Blood donation of approximately 1 pint (500 ml) within 56 days prior to dosing.

          -  A history of hypersensitivity to any of the study medications or related substances,
             or to any of the ingredients used in the study drug formulations.

          -  Unwilling or unable to comply with the Lifestyle guidelines described in this
             protocol.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.

          -  Recent history of diarrhea (2 weeks).

          -  Recent use of oral (2 weeks) or IV (2-3 months) antibiotics to assure normal bowel
             flora at study start.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dasmariñas City</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3801001&amp;StudyName=Bioequivalence%20Study%20Comparing%20Rifampicin%20In%20A%20Fixed-Dose%20Combination%20%28Rifampicin+Isoniazid%2C%20Myrin%A9%202%29%20And%20The%20Reference%20Drug%20%28Rifampi</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <results_first_submitted>March 23, 2012</results_first_submitted>
  <results_first_submitted_qc>June 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2012</results_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioequivalence; rifampicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of 22 participants enrolled, only 21 participants were randomized since 1 participant withdrew from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Myrin 2 First, Then Rimactane</title>
          <description>Single oral dose of 2 fixed dose combination (FDC) tablets of Myrin 2 (each tablet contains 150 milligram (mg) rifampicin and 75 mg isoniazid) in first intervention period, and single oral dose of Rimactane capsule (300 mg rifampicin) in second intervention period. A washout period of at least 7 days was maintained between each period.</description>
        </group>
        <group group_id="P2">
          <title>Rimactane First, Then Myrin 2</title>
          <description>Single oral dose of Rimactane capsule (300 mg rifampicin) in first intervention period; and single oral dose of 2 FDC tablets of Myrin 2 (each tablet contains 150 mg rifampicin and 75 mg isoniazid) in second intervention period. A washout period of at least 7 days was maintained between each period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period (at Least 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants Eligible for Analysis</title>
          <description>Includes participants randomized to receive Myrin 2 first and Rimactane first and who had completed the study. It excludes 1 participant who did not meet the weight requirement for the study (protocol violator).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 22 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23 to 27 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 to 32 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33 to 37 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])</title>
        <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hours (hrs) post-dose</time_frame>
        <population>Pharmacokinetic (PK) parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 mg rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane capsule (300 mg rifampicin) in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])</title>
          <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
          <population>Pharmacokinetic (PK) parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
          <units>microgram*hour/milliliter (mcg*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.59" spread="24.99"/>
                    <measurement group_id="O2" value="38.81" spread="21.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>20 participants (10 per sequence) provided at least 98% power that 90% confidence interval (CI) for ratio of test to reference for AUC(0-t) of rifampicin lie within acceptance region of 80%-125%. Intra-participant coefficient of variation (CV) estimate of approximately 13.48% for AUC(0-t) was used for this power calculation. Natural log transformed AUC(0-t) was analyzed using mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>98.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.98</ci_lower_limit>
            <ci_upper_limit>105.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 mg rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane capsule (300 mg capsule) in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>PK parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.89" spread="24.89"/>
                    <measurement group_id="O2" value="8.02" spread="22.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>20 participants (10 per sequence) provided at least 94% power that 90% CI for ratio of test to reference for Cmax of rifampicin lie within acceptance region of 80%-125%. Intra-participant CV estimate of approximately 16.43% for Cmax was used for this power calculation. Natural log transformed Cmax was analyzed using mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>98.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.77</ci_lower_limit>
            <ci_upper_limit>109.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 mg rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane capsule (300 mg rifampicin) in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <population>PK parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
          <units>hrs</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])</title>
        <description>AUC (0-∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 mg rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane capsule (300 mg rifampicin) in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])</title>
          <description>AUC (0-∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).</description>
          <population>PK parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
          <units>mcg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.72" spread="30.54"/>
                    <measurement group_id="O2" value="47.15" spread="25.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Natural log transformed AUC(0-∞) of rifampicin was analyzed using a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>100.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.44</ci_lower_limit>
            <ci_upper_limit>106.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Decay Half-life (t1/2)</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 mg rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane capsule (300 mg rifampicin) in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-life (t1/2)</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>PK parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
          <units>hrs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0750" spread="1.0777"/>
                    <measurement group_id="O2" value="3.8635" spread="0.8347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)</title>
        <description>AUC%extrapolated is the extrapolated area under the plasma concentration time profile following the last measured concentration. It is calculated as (AUC [0-∞] minus AUC[0-10])*100/ AUC (0-∞), where AUC (0-∞) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-10) = area under the plasma concentration time-curve from zero (pre-dose) to the last quantifiable concentration.</description>
        <time_frame>0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 mg rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane capsule (300 mg rifampicin) in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)</title>
          <description>AUC%extrapolated is the extrapolated area under the plasma concentration time profile following the last measured concentration. It is calculated as (AUC [0-∞] minus AUC[0-10])*100/ AUC (0-∞), where AUC (0-∞) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-10) = area under the plasma concentration time-curve from zero (pre-dose) to the last quantifiable concentration.</description>
          <population>PK parameter analysis population included all enrolled and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
          <units>Percent AUC</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.84" spread="38.47"/>
                    <measurement group_id="O2" value="17.53" spread="30.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Abnormal Safety Laboratory Test Values</title>
        <description>Participants were evaluated for following safety laboratory tests: Hematology, chemistry, urinalysis.</description>
        <time_frame>Screening and Follow-up (1 week post-baseline)</time_frame>
        <population>Safety population included participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane 300 mg capsule in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Safety Laboratory Test Values</title>
          <description>Participants were evaluated for following safety laboratory tests: Hematology, chemistry, urinalysis.</description>
          <population>Safety population included participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Change From Baseline Supine Blood Pressure (BP)</title>
        <description>Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.</description>
        <time_frame>Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)</time_frame>
        <population>Data was not summarized since supine systolic and diastolic BP remained within normal limits throughout the study and there were no significant deviations from baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane 300 mg capsule in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Change From Baseline Supine Blood Pressure (BP)</title>
          <description>Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.</description>
          <population>Data was not summarized since supine systolic and diastolic BP remained within normal limits throughout the study and there were no significant deviations from baseline.</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Change From Baseline Pulse Rate</title>
        <description>Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.</description>
        <time_frame>Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)</time_frame>
        <population>Data was not summarized since pulse rate remained within normal limits throughout the study and there were no significant deviations from baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane 300 mg capsule in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Change From Baseline Pulse Rate</title>
          <description>Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.</description>
          <population>Data was not summarized since pulse rate remained within normal limits throughout the study and there were no significant deviations from baseline.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Change From Baseline Oral Temperature</title>
        <description>Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.</description>
        <time_frame>Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)</time_frame>
        <population>Data was not summarized since oral temperature remained within normal limits throughout the study and there were no significant deviations from baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane 300 mg capsule in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Change From Baseline Oral Temperature</title>
          <description>Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.</description>
          <population>Data was not summarized since oral temperature remained within normal limits throughout the study and there were no significant deviations from baseline.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Change From Baseline Respiratory Rate</title>
        <description>Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.</description>
        <time_frame>Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)</time_frame>
        <population>Data was not summarized since respiratory rate remained within normal limits throughout the study and there were no significant deviations from baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane 300 mg capsule in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Change From Baseline Respiratory Rate</title>
          <description>Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.</description>
          <population>Data was not summarized since respiratory rate remained within normal limits throughout the study and there were no significant deviations from baseline.</population>
          <units>respirations/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>Any untoward medical occurrence in a participant who received study treatment was considered an AE without regard to possibility of causal relationship.</description>
        <time_frame>Baseline (Day 0), Day 1 and Follow-up (1 week post-baseline)</time_frame>
        <population>Safety population included participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Myrin 2</title>
            <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 rifampicin and 75 mg isoniazid.</description>
          </group>
          <group group_id="O2">
            <title>Rimactane</title>
            <description>Single oral dose of reference drug Rimactane 300 mg capsule in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>Any untoward medical occurrence in a participant who received study treatment was considered an AE without regard to possibility of causal relationship.</description>
          <population>Safety population included participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Myrin 2</title>
          <description>Single oral dose of 2 FDC tablets of Myrin 2 (Test) in either first intervention period or second intervention period. Each tablet contains 150 rifampicin and 75 mg isoniazid.</description>
        </group>
        <group group_id="E2">
          <title>Rimactane</title>
          <description>Single oral dose of reference drug Rimactane 300 mg capsule in either first intervention period or second intervention period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

